ADC targeting both PSMA and STEAP1 with a topoisomerase payload showed a 15-month PFS signal in heavily pretreated prostate cancer—far above historical chemotherapy benchmarks.
Tanya Barauskas Dorff, MD, FASCO
Advertisement
Articles by Tanya Barauskas Dorff, MD, FASCO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
How Often Do Health Insurers Deny Doctor-Recommended Care?
2
Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM
3
Sudden Death in HFpEF Often Preceded by Clinical Decline
4
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
5